Review of studies on metabolic genes and cancer in populations of African descent

Department of Epidemiology, State University of New York Downstate Medical Center, New York, NY 11203, USA.
Genetics in medicine: official journal of the American College of Medical Genetics (Impact Factor: 6.44). 12/2009; 12(1):12-8. DOI: 10.1097/GIM.0b013e3181c8e160
Source: PubMed

ABSTRACT Genetic polymorphisms described for a number of enzymes involved in the metabolism of tobacco carcinogens and alcohol have been linked to increase cancer risk. Racial disparities in cancer between whites and populations of African descent are well documented. In addition to differences in access to health care, both environment and genetic factors and their interaction may contribute to the increased cancer risk in minority populations. We reviewed the literature to identify case-control studies that included subjects of African descent. Meta-analyses investigating the association of genetic polymorphisms in tobacco metabolic genes and cancer were performed. Although several genes and cancers have been studied, only one or two studies per gene for each cancer site have been published, with the exception of breast (CYP1A1 and CYP1B1), lung (GSTM1, CYP1A1, and NQO1), and prostate (CYP3A4 A293G and CYP17). Marginal statistically significant associations were observed for CYP3A4 A293G and CYP17 5'UTR polymorphisms and prostate cancer. Our findings support the need for additional genetic association studies of breast, prostate, and lung cancers that include a larger number of minority participants. Because incidence and mortality rates for these cancers rank highest among populations of African descent, concentrated research in these areas are warranted.

Download full-text


Available from: Camille C Ragin, Jun 30, 2015
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Studies of cancer chemoprevention with caffeic acid phenethyl ester (CAPE) in the resistant hepatocyte model of hepatocarcinogenesis have shown the participation of CYP drug metabolizing enzymes. To prevent neoplastic and preneoplasic lesions, we must specifically identify which CYP activities are modified in the mechanism of action of CAPE. Male Fischer-344 rats were pretreated with CAPE twelve hours before administration of diethylnitrosamine (DEN) and were sacrificed twelve hours after CAPE and twelve hours, twenty-four hours, twenty-four days, and twelve months after DEN. Other rats were treated with the CYP inhibitors α-naphthoflavone or SKF525A and sacrificed twenty-four hours and twenty-four days after DEN. Microsomes were obtained from livers to quantify protein using Western blot. Diethylnitrosamine metabolism was measured based on nitrite formation and liver histology using GGT histochemistry. Caffeic acid phenethyl ester diminished the protein levels of CYP1A2 and CYP2B1/2. The inhibition of CYP2B1/2 prevented the appearance of preneoplastic lesions. Microsomal assays demonstrated that CAPE interfered with DEN activation diminishing nitrites similar to SKF525A and probably mediated by CYP2B1/2 inhibition. A single dose of CAPE before DEN treatment reduced the appearance of tumors by 43%. These results confirmed that CAPE is a promising agent to confer chemoprotection in liver cancer and should be considered for human therapies.
    Toxicologic Pathology 01/2012; 40(3):466-72. DOI:10.1177/0192623311431947 · 1.92 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Polymorphisms in DNA repair genes have been reported contributing factors in head and neck cancer risk but studies have shown conflicting results. To clarify the impact of DNA repair gene polymorphisms in head and neck cancer risk. A meta-analysis including 30 case-control studies was performed. Marginally statistically significant association was found for XRCC1 codon 399 (for Caucasians only), XPD Asp312Asn and XRCC1 codon 194 variants and head and neck cancer. Assessments of the effects of smoking, alcohol, human papillomavirus and race/ethnicity on the association between DNA repair gene polymorphisms and head and neck cancer are needed.
    Biomarkers 08/2010; 15(5):379-99. DOI:10.3109/13547501003797664 · 2.52 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: This study compares the clinical presentation and characteristics of lung cancer among white and black patients according to place of birth, and correlates these factors to outcome. All newly diagnosed lung cancers from 2005 to 2007 in three tertiary medical centers were retrospectively reviewed; 767 patients were identified, 252 of whom were black. Age, sex, family history, place of birth, smoking history, insurance status, clinical stage, histology, grade of differentiation, symptoms, circumstance of diagnosis, treatment and outcome data were retrieved from medical charts. Lung cancer was diagnosed incidentally in 28.2% of white individuals versus 12.3% in black individuals (p < 0.0001). After adjustment for other variables, black and white individuals have similar survival rates (hazard ratio: 1.3; 95% CI: 0.8-2.0). The differences in lung cancer survival could be related to access to care, environmental factors and the biology of the disease. Including place of birth in cancer outcome studies could help understanding the origin of health disparity.
    Future Oncology 08/2010; 6(8):1353-61. DOI:10.2217/fon.10.89 · 2.61 Impact Factor